智通财经APP讯,金斯瑞生物科技(01548)发布公告,根据传奇生物科技股份有限公司(为公司联营公司,其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)与Janssen Biotech, Inc.(杨森)于2017年12月21日订立的合作及许可协议,CARVYKTI®于截至2026年3月31日止季度产生贸易销售净额约5.97亿美元。
智通财经APP讯,金斯瑞生物科技(01548)发布公告,根据传奇生物科技股份有限公司(为公司联营公司,其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)与Janssen Biotech, Inc.(杨森)于2017年12月21日订立的合作及许可协议,CARVYKTI®于截至2026年3月31日止季度产生贸易销售净额约5.97亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.